methyl 4-(1-methyl-1H-tetrazol-5-ylthio)butyrate | 80086-15-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: methyl 4-(1-methyl-1H-tetrazol-5-ylthio)butyrate
• 英文别名: methyl 4-(1-methyl-1,2,3,4-tetrazol-5-yl)thio-butyrate；Methyl 4-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]butanoate；methyl 4-(1-methyltetrazol-5-yl)sulfanylbutanoate
• CAS: 80086-15-3
• 化学式: C₇H₁₂N₄O₂S
• 分子量: 216.264
• InChiKey: VNYHWUYDSLKCJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  95.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 4-(1-methyl-1H-tetrazol-5-ylthio)butyrate 在 盐酸 、 氯化亚砜 作用下， 反应 2.0h， 生成 4-(1-methyl-1,2,3,4-tetrazol-5-yl)thio-butyryl chloride
  参考文献：
  名称：

  胃抗溃疡活性剂的研究。二。四唑烷酰胺和相关化合物的合成。

  摘要：

  合成了一系列四唑烷酰胺，并测试了其对乙酸诱导的大鼠胃溃疡的抗溃疡活性。这些化合物是通过四唑链烷酸与各种胺通过混合酸酐法或酰氯法反应制得的。其中，发现3-[（（1-乙基-5-四唑基）甲硫基]丙酰胺（IIn）具有最强的活性。讨论了构效关系。

  DOI：

  10.1248/cpb.37.322
• 作为产物：
  描述：

  4-溴丁酸甲酯 、 1-甲基-5-巯基-1H-四氮唑 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 4.0h， 生成 methyl 4-(1-methyl-1H-tetrazol-5-ylthio)butyrate
  参考文献：
  名称：

  胃抗溃疡活性剂的研究。二。四唑烷酰胺和相关化合物的合成。

  摘要：

  合成了一系列四唑烷酰胺，并测试了其对乙酸诱导的大鼠胃溃疡的抗溃疡活性。这些化合物是通过四唑链烷酸与各种胺通过混合酸酐法或酰氯法反应制得的。其中，发现3-[（（1-乙基-5-四唑基）甲硫基]丙酰胺（IIn）具有最强的活性。讨论了构效关系。

  DOI：

  10.1248/cpb.37.322

文献信息

• Tetrazole derivatives, anti-ulcer composition containing the same and
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：US04540703A1

  公开（公告）日：1985-09-10

  Tetrazole derivatives of the formula: ##STR1## wherein R.sup.1 is an optional defined substituent; A is sulfur or a lower alkylene-thio; l is 0 or 1; B is a lower alkylene; R.sup.2 is hydroxy, a lower alkoxy, or a group: ##STR2## wherein R.sup.3 and R.sup.4 are optional defined substituents, or the R.sup.3 and R.sup.4 may combine together with the nitrogen atom to which they are joined to form a defined heterocyclic group, and a pharmaceutically acceptable salt thereof, which have prophylactic or therapeutic activities against peptic and/or duodenal ulcers and also anti-inflammatory activity and are useful as an anti-ulcer or anti-inflammatory drug; processes for the preparation of the tetrazole derivatives; and pharmaceutical composition containing said tetrazole derivatives.

  四唑衍生物的化学式为：##STR1## 其中R.sup.1是可选的定义取代基；A是硫或较低的烷基硫；l为0或1；B是较低的烷基；R.sup.2是羟基、较低的烷氧基或一个基团：##STR2## 其中R.sup.3和R.sup.4是可选的定义取代基，或者R.sup.3和R.sup.4可以与它们结合的氮原子一起形成一个定义的杂环基，并且其药学上可接受的盐，具有预防或治疗胃溃疡和/或十二指肠溃疡的活性，以及抗炎活性，并且可用作抗溃疡或抗炎药物；四唑衍生物的制备方法；以及含有该四唑衍生物的药物组合物。
• Antiulcer Agents. II. Synthesis and Gastric Acid Antisecretory Activity of N-(3-{3-(Piperidinomethyl)phenoxy}propyl)-4-(1-methyl-1H-tetrazol-5-ylthio)butanamide and Related Compounds.
  作者：Ikuo UEDA、Katsuyuki ISHII、Katsuo SINOZAKI、Masao SEIKI、Minoru HATANAKA

  DOI：10.1248/cpb.39.1430

  日期：——

  N-[3-3-(Piperidinomethyl)phenoxy}propyl]butanamides having a 1-methyl-1H-tetrazol-5-ylthio moiety as a pharmacophore and related compounds were prepared and tested for their antisecretory activity against histamine-induced gastric acid secretion in conscious rats with gastric fistulas. Most of the compounds showed antisecretory activity. Among them, N-[3-3-(piperidinomethyl)phenoxy}propyl]-4-(1-methyl-1H-tetrazol-5-ylthio)butanamide (5f) was found to possess the most potent activity, and a possibility of isosteric replacement of the methoxycarbonyl group with 1-methyl-1H-tetrazol-5-yl group was indicated. The structure-activity relationships are also discussed.

  本研究制备了以 1-甲基-1H-四唑-5-硫基为药理基础的 N-[3-3-(哌啶甲基)苯氧基}丙基]丁酰胺类化合物及相关化合物，并测试了它们对患有胃瘘的清醒大鼠组胺诱导的胃酸分泌的抗分泌活性。大多数化合物都显示出了抗分泌活性。其中，N-[3-3-(哌啶甲基)苯氧基}丙基]-4-(1-甲基-1H-四唑-5-硫基)丁酰胺（5f）具有最强的活性，并表明了甲氧基羰基被 1-甲基-1H-四唑-5-基团等位取代的可能性。此外，还讨论了结构-活性关系。
• Tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0035228A1

  公开（公告）日：1981-09-09

  Tetrazole derivatives of the formula: wherein R1 is a lower alkyl, phenyl or a group of the formula: -S(O)ℓ-A-(X)m-R3, and R2 is hydrogen, a lower alkyl, phenyl or a cycloalkyl when R' is the group-S(O)ℓ-A-(X)m--R3, or R2 is a group of the formula: -B-CO-R4 when R1 is a lower alkyl or phenyl and a pharmaceutically acceptable salt thereof, which have prophylactic or therapeutic activities against peptic and/or duodenal ulcers and are useful as an anti-ulcer drug; processes for the preparation of the tetrazole derivatives; and pharmaceutical composition containing said tetrazole derivatives.

  式中的四唑衍生物： 其中 R1 是低级烷基、苯基或式中的基团：-R2是氢、低级烷基、苯基或环烷基，当R'是式中的基团-S(O)ℓ-A-(X)m--R3，或R2是式中的基团：-B-CO-R4（当 R1 为低级烷基或苯基时）及其药学上可接受的盐，对消化性溃疡和/或十二指肠溃疡具有预防或治疗活性，可用作抗溃疡药物；四唑衍生物的制备工艺；以及含有上述四唑衍生物的药物组合物。
• Novel tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0035046A1

  公开（公告）日：1981-09-09

  Tetrazole derivatives of the formula: wherein R1 is an optional defined substituent; A is sulfur or a lower alkylene-thio; I is 0 or 1; B is a lower alkylene; R2 is hydroxy, a lower alkoxy, or a group: wherein R3 and R4 are optional defined substituents, or the R3 and R4 may combine together with the nitrogen atom to which they are joined to form a defined heterocyclic group, and a pharmaceutically acceptable salt thereof, which have prophylactic or therapeutic activities against peptic and/or duodenal ulcers and also anti-inflammatory activity and are useful as an anti-ulcer or anti-inflammatory drug; processes for the preparation of the tetrazole derivatives; and pharmaceutical composition containing said tetrazole derivatives.

  式中的四唑衍生物： 其中 R1 是任选的定义取代基；A 是硫或低级亚烷基硫基；I 是 0 或 1；B 是低级亚烷基；R2 是羟基、低级烷氧基或基团： 其中 R3 和 R4 是任选的定义取代基，或 R3 和 R4 可与它们连接的氮原子结合在一起形成定义的杂环基团，以及其药学上可接受的盐，它们对消化性和/或十二指肠溃疡具有预防或治疗活性，还具有抗炎活性，可用作抗溃疡或抗炎药物；四唑衍生物的制备工艺；以及含有所述四唑衍生物的药物组合物。
• UCHIDA, MINORU;NISHI, TAKAO;NAKAGAWA, KAZUYUKI
  作者：UCHIDA, MINORU、NISHI, TAKAO、NAKAGAWA, KAZUYUKI

  DOI：——

  日期：——